{"filings":[{"id":471720,"accession_number":"0001193125-26-226968","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-05-15T20:31:27+00:00","items":["5.07"],"status":"ready","headline":"Prothena shareholders re-elect directors, ratify auditor, approve exec comp at 2026 AGM","event_type":"other","confidence":"high","bullets":["Shane M. Cooke re-elected with 22,720,769 for, 11,923,467 against, 9,139 abstain.","Dennis J. Selkoe re-elected with 25,226,560 for, 9,420,544 against, 6,271 abstain.","KPMG ratified as 2026 auditor: 41,931,718 for, 82,815 against, 12,984 abstain (binding).","Non-binding say-on-pay approved: 32,303,076 for, 1,145,400 against, 1,204,899 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93625,"accession_number":"0001559053-26-000016","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance","event_type":"earnings","confidence":"high","bullets":["Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.","Revenue $51.1M (vs $2.8M), primarily from $50M Novo Nordisk milestone for coramitug Phase 3 enrollment.","Updated FY2026 net cash used guidance to $18-23M (prior $50-55M); year-end cash ~$273M (midpoint), up $18M.","Initiated up to $100M share repurchase program; repurchased 788,990 shares for $7.3M through Q1.","PRX019 Phase 1 completed; potential $55M milestone if Bristol Myers Squibb advances by YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":51084000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105412,"accession_number":"0001559053-26-000009","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Prothena authorizes up to $100M share repurchase plan through Dec 31, 2026","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $100M of ordinary shares; plan expires Dec 31, 2026.","Company had $308.4M cash and no debt as of Dec 31, 2025.","Guidance (excluding buyback) expects ~$255M cash at year-end 2026.","Potential to earn up to $105M in clinical milestone payments from partners in 2026.","Repurchases are discretionary; no obligation to buy any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105411,"accession_number":"0001559053-26-000003","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M","event_type":"earnings","confidence":"high","bullets":["Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).","Total revenue $21K in Q4 vs $2.1M a year ago; full-year revenue $9.7M vs $135.2M in 2024.","Cash & restricted cash $308.4M at Dec 31, 2025; no debt; shares outstanding ~53.8M.","2026 guidance: net cash used in ops $50-55M; year-end cash ~$255M; excludes up to $105M milestones.","Partners Roche, Novo Nordisk, BMS initiated Phase 3 trials for prasinezumab, coramitug, and BMS-986446."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":9684000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121689,"accession_number":"0001559053-25-000049","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prothena board member Paula Cobb resigns effective Dec 31, 2025","event_type":"leadership","confidence":"high","bullets":["Paula Cobb notified Prothena of her resignation from the Board, effective December 31, 2025.","She will continue serving on the Board, Compensation Committee, and Audit Committee through that date.","Resignation is not due to any disagreement with the Company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121688,"accession_number":"0001559053-25-000047","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve capital reduction to create distributable reserves","event_type":"other","confidence":"high","bullets":["37.8M votes for, 46.7K against, 45.9K abstained at extraordinary general meeting on Nov 19, 2025.","Reduction of capital creates distributable reserves for potential future dividends or buybacks.","Meeting was held virtually; proposal described in proxy statement filed Oct 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121687,"accession_number":"0001559053-25-000042","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).","Revenue fell to $2.4M in Q3 2025 from $1.0M in Q3 2024; nine-month revenue $9.7M vs $133.0M primarily from BMS collaboration.","Cash and equivalents $331.7M; no debt. FY2025 guidance: net cash used $170-178M, year-end cash ~$298M midpoint.","Roche to initiate Phase 3 PARAISO prasinezumab trial for Parkinson's by end 2025; Novo Nordisk started Phase 3 CLEOPATTRA for coramitug in ATTR-CM.","EGM on Nov 19 to vote on share capital reduction to support potential 2026 share redemption program; up to $105M in clinical milestones by end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":9663000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138368,"accession_number":"0001193125-25-189765","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership","event_type":"other_material","confidence":"high","bullets":["Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.","ARIA-E rates at 400 mg (41.7%) and 200 mg (38.1%) exceeded those of FDA-approved anti-Aβ antibodies.","One death in 45 mg cohort deemed unrelated to study drug; injection site reactions low (4.1%).","Company plans to explore partnership to advance PRX012 and preclinical PRX012-TfR antibody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138367,"accession_number":"0001193125-25-174061","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM","event_type":"other_material","confidence":"high","bullets":["Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.","Prothena eligible for up to $1.2B in milestones, $100M received to date.","Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.","Coramitug is a potential first-in-class amyloid depleter antibody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138366,"accession_number":"0001559053-25-000029","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025","event_type":"earnings","confidence":"high","bullets":["Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.","Revenue $4.4M, down from $132.0M YoY; cash $372.3M with no debt; FY 2025 cash burn guidance $170-178M.","Partner Roche plans Phase 3 start for prasinezumab in early Parkinson's by end 2025; peak sales potential >$3B.","Initial Phase 1 data for PRX012 in Alzheimer's expected August 2025; up to $105M milestones possible in 2026.","Prothena to hold EGM by year-end to vote on share capital reduction for potential share redemption program."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":7248000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138365,"accession_number":"0001193125-25-169367","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prothena Biosciences enters employment agreements with CFO, COO, CSO; base salaries set at $518K-$604K","event_type":"other_material","confidence":"high","bullets":["CFO Tran Nguyen base $603,792 (50% bonus target); COO Brandon Smith $544,201 (50%); CSO Wagner Zago $518,000 (40%).","Severance without cause or for good reason: 100% base salary, 100% target bonus, up to 12 months COBRA.","Change-in-control severance: 150% base, 150% target bonus, up to 18 months COBRA plus equity acceleration.","Agreements memorialize benefits consistent with existing severance plan; no change in roles or compensation levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155815,"accession_number":"0001193125-25-142725","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1","event_type":"leadership","confidence":"high","bullets":["Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.","Expected severance and benefits $16-20M plus non-cash stock option acceleration.","Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford to depart Aug 1, 2025.","Follows May 23 decision to discontinue birtamimab development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155814,"accession_number":"0001193125-25-141098","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint","event_type":"other_material","confidence":"high","bullets":["Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.","Phase IIb PADOVA study missed statistical significance on primary endpoint but showed positive trends in motor progression.","Open-label extension data suggest sustained clinical benefit over longer treatment periods.","First biomarker evidence from PADOVA indicates impact on underlying disease biology.","Over 10 million people affected globally; potential first disease-modifying treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155813,"accession_number":"0001193125-25-125881","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Prothena's Phase 3 AFFIRM-AL trial for birtamimab fails; development halted; workforce reduction planned","event_type":"other_material","confidence":"high","bullets":["Phase 3 AFFIRM-AL did not meet primary endpoint of all-cause mortality (HR=0.915, p=0.7680); secondary endpoints also missed.","Birtamimab development discontinued; open-label extension stopped.","Company to substantially reduce workforce and operating expenses; further update expected in June 2025.","Birtamimab was generally safe and well-tolerated, consistent with prior safety profile.","Upcoming data: PRX012 Phase 1 ASCENT (Alzheimer's) in August; partner updates from Roche, Novo Nordisk, BMS in 2025-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155812,"accession_number":"0001559053-25-000025","cik":1559053,"company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Prothena shareholders approve 2M share increase to LTIP, re-elect all directors","event_type":"other_material","confidence":"high","bullets":["Shareholders approved an amendment increasing shares under the 2018 LTIP by 2,000,000, effective May 13, 2025.","Directors Paula Cobb, Lars Ekman, and Gene Kinney re-elected to terms through 2028; Kinney had 9.7M against.","Advisory vote on named executive officer compensation passed with 34.7M for vs 11.2M against.","Ratification of KPMG as independent auditor for FY2025 passed with 50.3M for.","Amendment sets overall share limit to 13,100,000 plus prior plan carryover shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}